| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Aug―14 |
Noncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites |
Dipendra Bhandari, Katerina Kovalevskaya, Leighton Coates, Colleen Jonsson, Jyothi Parvathareddy, Kevin L Weiss, Annie Aniana, John M Louis, Peter Bonnesen, Andrey Kovalevsky |
| 2 |
[GO] |
2026―Jun―29 |
Design, synthesis, and X-ray structural studies of potent SARS-CoV-2 Mpro inhibitors containing tetrahydroisoquinoline-3-carboxamides as P2 ligands |
Arun K. Ghosh, Ashish Sharma, Satyanarayana Iddum, Sydney N. Bogan, Uttara Jayashankar, Emma K. Lendy, Shin-ichiro Hattori, Nobuyo Higashi-Kuwata, Hiroaki Mitsuya, Andrew D. Mesecar |
| 3 |
[GO] |
2026―Jan―13 |
Integrated computational screen and validation of thalidomide-based PROTACs targeting SARS-CoV-2 main protease |
Li-Na Guo, Yu-Hua Li, Rou-Yu Zhu, Ni Su, Zhi-Yu Shao, Hua Diao |
| 4 |
[GO] |
2026―Jan―06 |
Crystallographic characterisation and development of bi-substrate inhibitors of coronavirus nsp14 methyltransferase |
Irene Georgiou, Colin Robinson, Sean N. O'Byrne, Alex Matsuda, Przemysław Grygier, Craig D. Smith, Sandra O'Neill, Shamshad A. Ahmad, Suzanne Norval, John M. Post, Mirjam Groenewold, Nadya Urakova, Patrick Wanningen, Leanid Kresik, Jacek Plewka, Adrien Delpal, Kexin See, Thomas Eadsforth, Kinga Wierzbicka, Etienne Decroly, Kumar Singh Saikatendu, Edcon Chang, Eric J. Snijder, Krzysztof Pyrć, Anna Czarna, Duncan E. Scott, Ian H. Gilbert |
| 5 |
[GO] |
2025―Oct―27 |
C6-Alkoxy substituted penicillins are potent non-covalently binding inhibitors of the SARS-CoV-2 main protease |
Dorian-Gabriel Muntean, Wojtek Treyde, Linda Kinena, Eidarus Salah, Hani Choudhry, Fernanda Duarte, Lennart Brewitz, Christopher J. Schofield |
| 6 |
[GO] |
2025―Aug―15 |
Structural insights into the nirmatrelvir-resistant SARS-CoV-2 Mpro L50F/E166A/L167F triple mutant-inhibitor-complex reveal strategies for next generation coronaviral inhibitor design |
Conrad Fischer, Jimmy Lu, Marco J. van Belkum, Sydney Demmon, Pu Chen, Chaoxiang Wang, Tayla J. Van Oers, Tess Lamer, M. Joanne Lemieux, John C. Vederas |
| 7 |
[GO] |
2025―Aug―12 |
Bicyclic Temporin L Peptide Inhibitors Targeting SARS-CoV-2 Main Protease: Design, Synthesis, In-Vitro Inhibition Efficiency and Molecular Dynamics Insights |
Md Taimuzzaman Sharif, Md. Omor Farque, Md Habibur Rahaman, Md. Arafat Hossen, Akhter Hossain, Mohammad A Halim |
| 8 |
[GO] |
2025―Feb―13 |
Transmembrane protease serine 2 (TMPRSS2) inhibitors screened from an Fv-antibody library for preventing SARS-CoV-2 infection |
Jaeyong Jung, Jeong Soo Sung, Soonil Kwon, Hyung Eun Bae, Min-Jung Kang, Joachim Jose, Misu Lee, Jae-Chul Pyun |
| 9 |
[GO] |
2024―Dec―23 |
Targeting host integrated stress response: lead discovery of flavonoid compounds active against coronaviruses PEDV and PDCoV |
Liang Yi, Yishuai Wang, Jiehuang Wang, Yihan Chen, Weixue Huang, Ying Liao, Qingwen Zhang |
| 10 |
[GO] |
2024―Oct―18 |
Miniaturized Click Chemistry and Direct Screening Facilitate the Discovery of Triazole Piperazine SARS-CoV-2 Mpro Inhibitors with Improved Metabolic Stability |
Shenghua Gao, Letian Song, Bing Ye, Mianling Yang, Junyi Li, Manyu Gu, Ann. E Tollefson, karoly Toth, Peng Zhan, Xinyong Liu |
| 11 |
[GO] |
2024―Sep―27 |
Discovery of a Nasal Spray Steroid, Tixocortol, as an Inhibitor of SARS-CoV-2 Main Protease and Viral Replication |
David A Davis, Ashwin Nair, Yana Astter, Emma Treco, Brian Daniel Peyser, Rick Gussio, Tam Nguyen, Brett Eaton, Elena Postnikova, Michael Murphy, Prabha Shrestha, Haydar Bulut, Shin-ichiro Hattori, Hiroaki Mitsuya, Robert Yarchoan |
| 12 |
[GO] |
2024―Sep―26 |
Exploring 7β-Amino-6-Nitrocholestens as COVID-19 Antivirals: In silico, Synthesis, Evaluation, and Integration of Artificial Intelligence (AI) in Drug Design: Assessing the Cytotoxicity and Antioxidant Activity of 3β-Acetoxynitrocholestane |
Shahabuddin ., Uzma ., Mohammad Azam, mehtab parveen, N.H.A. Kadir, Kim Min, Mahboob Alam |
| 13 |
[GO] |
2024―Sep―16 |
Inhibition of SARS-CoV-2 3CLpro by chemically modified tyrosinase from Agaricus bisporus |
David Aguilera-Rodriguez, David Ortega-Alarcon, Angela Vazquez-Calvo, Veronica Ricci, Olga Abian, Adrian Velazquez-Campoy, Antonio Alcami, Jose M. Palomo |
| 14 |
[GO] |
2024―Sep―03 |
Asymmetric imidazole-4,5-dicarboxamides derivatives as SARS-CoV-2 main protease inhibitors: Design, Synthesis and Biological Evaluation |
Phuong Nguyen Hoai Huynh, Phatcharin Khamplong, Minh-Hoang Phan, Thanh-Phuc Nguyen, Phuong Vu Ngoc Lan, Quang-Vinh Tang, Phumin Chamsodsai, Supaphorn Seetaha, Truong Lam Tuong, Thien-Y Vu, Duc-Duy Vo, Kiattawee Choowongkomon, Cam-Van Thi Vo |
| 15 |
[GO] |
2024―Aug―26 |
Preventing SARS-CoV-2 infection using Fv-antibodies targeting the proprotein convertase (PPC) cleavage site |
Jaeyong Jung, Jeong Soo Sung, Soonil Kwon, Hyung Eun Bae, Min-Jung Kang, Joachim Jose, Misu Lee, Jae-Chul Pyun |
| 16 |
[GO] |
2024―Aug―16 |
Inhibiting SARS-CoV-2 viral entry by targeting spike:ACE2 interaction with O-modified quercetin derivatives |
Reuben James Z. Rosal, Monissa C. Paderes |
| 17 |
[GO] |
2024―Aug―01 |
Discovery of highly potent SARS-CoV-2 nsp14 methyltransferase inhibitors based on adenosine 5′-carboxamides |
Hugo Kocek, Dominika Chalupská, Milan Dejmek, Alexandra Dvořáková, Michala Zgarbová, Michal Šála, Karel Chalupský, Petra Krafčíková, Tomáš Otava, Matus Drexler, Eliška Procházková, Blanka Klepetářová, Milan Štefek, Ján Kozic, Helena Mertlíková-Kaiserová, Evzen Boura, Jan Weber, Radim Nencka |
| 18 |
[GO] |
2024―Apr―29 |
Identification of SARS-CoV-2 Mpro inhibitors through deep reinforcement learning for de novo drug design and computational chemistry approaches |
Julien Hazemann, Thierry Kimmerlin, Roland Lange, Aengus MacSweeney, Geoffroy Bourquin, Daniel Ritz, Paul Czodrowski |
| 19 |
[GO] |
2024―Jan―26 |
N-arylsulfonamide-based adenosine analogues to target RNA cap N7-methyltransferase nsp14 of SARS-CoV-2 |
Rostom Ahmed-Belkacem, Joris Troussier, Adrien Delpal, Bruno Canard, Jean-Jacques Vasseur, Etienne DECROLY, Françoise Debart |
| 20 |
[GO] |
2023―Nov―28 |
NMR 1H,19F-based screening of the four stem-looped structure 5_SL1-SL4 located in the 5′-untranslated region of SARS-CoV 2 RNA |
Daniel Hymon, Jason Martins, Christian Richter, Sridhar Sreeramulu, Anna Wacker, Jan Ferner, Neeraj N. Patwardhan, Amanda E. Hargrove, Harald Schwalbe |
| 21 |
[GO] |
2023―Oct―13 |
On the origins of SARS-CoV-2 main protease inhibitors |
Yves L. Janin |
| 22 |
[GO] |
2023―Aug―17 |
Identification of Novel 1,2,3-triazole Isatin Derivatives as Potent SARS-CoV-2 3CLpro Inhibitors via Click-chemistry-based Rapid Screening |
Xiangyi Jiang, Jing Li, Antonio Viayna, F. Javier Luque, Molly Woodson, Lanlan Jing, Shenghua Gao, Fabao Zhao, Minghui Xie, karoly Toth, John Tavis, Ann. E Tollefson, Xinyong Liu, Peng Zhan |
| 23 |
[GO] |
2023―Jul―31 |
De novo design of a stapled peptide targeting SARS-CoV-2 spike protein receptor-binding domain |
Ravindra Thakkar, Dilip K. Agarwal, Chathuranga B. Ranaweera, Susumu Ishiguro, Martin Conda-Sheridan, Natasha N. Gaudreault, Juergen A. Richt, Masaaki Tamura, Jeffrey Comer |
| 24 |
[GO] |
2023―May―16 |
Silver N-heterocyclic carbene complexes are potent uncompetitive inhibitors of the papain-like protease with antiviral activity against SARS-CoV-2 |
Maria Gil-Moles, Cillian O'Beirne, Igor V. Esarev, Petra Lippmann, Matthias Tacke, Jindrich Cinatl Jr., Denisa Bojkova, Ingo Ott |
| 25 |
[GO] |
2023―Mar―21 |
Insights Into Targeting the SARS-CoV-2: Design, Synthesis, In Silico Studies and Antiviral Evaluation of New Dimethylxanthine Derivatives |
Abdalla R. Mohamed, Ahmed Mostafa, Mahmoud A. El Hassab, Gomaa M. Hedeab, Sara H. Mahmoud, Riham F. George, Hanan H. Georgey, Nagwa M. Abdel Gawad, Mohamed K. El-Ashrey |
| 26 |
[GO] |
2023―Jan―25 |
Design and Synthesis of Naturally-Inspired SARS-CoV-2 Inhibitors |
Haitham Hassan, Jeanne Chiaravalli, Afnan Hassan, Loay Bedda, Tim Krischuns, Kuang-Yu Chen, Alice Shi Ming Li, Adrien Delpal, Etienne Decroly, Masoud Vedadi, Nadia Naffakh, Fabrice Agou, Sergio Mallart, Reem K. Arafa, Paola B. Arimondo |
| 27 |
[GO] |
2022―Nov―18 |
Synthesis of bis-furyl-pyrrolo[3,4-b]pyridin-5-ones via Ugi-Zhu Reaction and In Vitro Activity Assays Against Human SARS-CoV-2 and In Silico Studies on its main Proteins |
Ivette Morales-Salazar, Flora P. Montes-Enríquez, Carlos E. Garduño-Albino, M. A. Garcia-Sanchez, Ilich A. Ibarra, Yareli Rojas-Aguirre, Montserrat Elemi García-Hernández, Rosa Elena Sarmiento-Silva, Sofía Lizeth Alcaraz-Estrada, Erik Díaz-Cervantes, Eduardo González-Zamora, Alejandro Islas-Jácome |
| 28 |
[GO] |
2022―Oct―27 |
Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020 |
Roufen Chen, Yali Gao, Han Liu, He Li, Wenfa Chen, Junjie Ma |
| 29 |
[GO] |
2022―Oct―14 |
Design, Synthesis and Immunological Evaluation of Monophosphoryl Lipid A Derivatives as Adjuvants for RBD-hFc Based SARS-CoV-2 Vaccine |
Shiwei Su, Liqing Chen, Menglan Yang, Dan Liang, Bixia ke, Zhongqiu Liu, Changwen Ke, Guochao Liao, Liang Liu, Xiang Luo |
| 30 |
[GO] |
2022―Jan―25 |
An insight into SARS-CoV2 structure, Pathogenesis, target hunting for drug development and vaccine initiatives |
Arijit Ghosh, Paritosh k. Kar, Anupam Gautam, Rahul Gupta, Rajveer Singh, Rudra chakravarti, Ravichandiran Velayutham, Subhra Ghosh dastidar, Dipanjan Ghosh, Syamal Roy |
| 31 |
[GO] |
2021―Sep―07 |
Synthesis of low-molecular weight fucoidan derivatives and their binding abilities to SARS-CoV-2 spike proteins |
Tatsuki Koike, Aoi Sugimoto, Shuhei Kosono, Sumika Komaba, Yuko Kanno, Takashi Kitamura, Itsuki Anzai, Tokiko Watanabe, Daisuke Takahashi, Kazunobu Toshima |
| 32 |
[GO] |
2021―Aug―20 |
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors |
Bing Bai, Elena Arutyunova, Muhammad Bashir Khan, Jimmy Lu, Michael A. Joyce, Holly Saffran, Justin A. Shields, Appan Srinivas Kandadai, Alexandr Belovodskiy, Mostofa Hena, Wayne Vuong, Tess Lamer, Howard young, John C Vederas, D. Lorne Tyrrell, Joanne Lemieux, James Nieman |
| 33 |
[GO] |
2021―Aug―18 |
A novel compound active against SARS-CoV-2 targeting Uridylate-specific endoribonuclease (NendoU/NSP15): In silico and in vitro investigations |
Sumit Kumar, Yash Gupta, Samantha Zak, Charu Upadhyay, Neha Sharma, Andrew Herbert, Ravi Durvasula, Vladimir Potemkin, John Dye, Poonam Singh, Prakasha Kempaiah, Brijesh Rathi |
| 34 |
[GO] |
2021―Apr―15 |
A review of latest research on Mpro targeted SARS-COV inhibitors |
Huihui Yang, Jinfei Yang |
| 35 |
[GO] |
2020―Dec―21 |
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics |
Rick Oerlemans, Angel Jonathan Ruiz-Moreno, Yingying Cong, Nilima Dinesh Kumar, Marco A. Velasco-Velazquez, Constantinos G. Neochoritis, Jolanda Smith, Fulvio Reggiori, Matthew R. Groves, Alexander Dömling |
| 36 |
[GO] |
2020―Dec―17 |
Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides |
Sebastian Pomplun |
| 37 |
[GO] |
2020―Nov―02 |
Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (MPRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model |
Lucas S. Franco, Rodolfo C. Maia, Eliezer J. Barreiro |
|
